Q2 EPS Estimates for Biomea Fusion Lifted by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for Biomea Fusion in a note issued to investors on Monday, June 23rd. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.46) per share for the quarter, up from their prior forecast of ($0.66). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Biomea Fusion's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.

BMEA has been the topic of a number of other research reports. Oppenheimer set a $10.00 price objective on Biomea Fusion in a research report on Monday, March 24th. Piper Sandler initiated coverage on Biomea Fusion in a research report on Tuesday, June 3rd. They set an "overweight" rating and a $7.00 price objective on the stock. Barclays dropped their target price on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 2nd. Finally, D. Boral Capital reissued a "buy" rating and issued a $16.00 target price on shares of Biomea Fusion in a report on Tuesday, June 24th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $21.40.

Biomea Fusion Stock Performance

Shares of Biomea Fusion stock traded down $0.18 during trading hours on Thursday, reaching $1.81. 4,503,914 shares of the company were exchanged, compared to its average volume of 1,147,460. Biomea Fusion has a 1 year low of $1.29 and a 1 year high of $13.07. The stock's fifty day moving average is $1.94 and its 200 day moving average is $2.82. The firm has a market cap of $68.00 million, a PE ratio of -0.51 and a beta of -0.23.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.04.

Institutional Trading of Biomea Fusion

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in Biomea Fusion by 98.0% in the 4th quarter. Bank of America Corp DE now owns 51,180 shares of the company's stock valued at $199,000 after acquiring an additional 25,332 shares during the period. Northern Trust Corp increased its position in Biomea Fusion by 3.9% in the 4th quarter. Northern Trust Corp now owns 322,650 shares of the company's stock valued at $1,252,000 after acquiring an additional 12,210 shares during the period. Wellington Management Group LLP acquired a new position in Biomea Fusion in the 4th quarter valued at about $317,000. Exchange Traded Concepts LLC increased its position in Biomea Fusion by 140.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 50,550 shares of the company's stock valued at $108,000 after acquiring an additional 29,565 shares during the period. Finally, Two Sigma Investments LP increased its position in Biomea Fusion by 104.4% in the 4th quarter. Two Sigma Investments LP now owns 559,930 shares of the company's stock valued at $2,173,000 after acquiring an additional 286,049 shares during the period. Institutional investors and hedge funds own 96.72% of the company's stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.